Corcept Therapeutics 과거 순이익 실적
과거 기준 점검 1/6
Corcept Therapeutics의 수입은 연평균 -2.7%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 수입이 연평균 13.5% 증가했습니다. 매출은 연평균 19.1%의 비율로 증가해 왔습니다. Corcept Therapeutics의 자기자본이익률은 7.8%이고 순이익률은 6.5%입니다.
핵심 정보
-2.74%
순이익 성장률
-0.49%
주당순이익(EPS) 성장률
| Pharmaceuticals 산업 성장률 | 5.95% |
| 매출 성장률 | 19.09% |
| 자기자본이익률 | 7.82% |
| 순이익률 | 6.53% |
| 최근 순이익 업데이트 | 30 Jun 2026 |
최근 과거 실적 업데이트
Recent updates
내러티브 업데이트 • Sep 03
CORT: Cushing’s And Oncology Franchise Expansion Will Drive Future Upside
Analysts have lifted their fair value estimate for Corcept Therapeutics from $121 to $165, citing higher projected revenue growth, stronger profit margins, and a lower assumed future P/E multiple. This follows recent research that highlights Lifyorli's early oncology traction, ongoing Cushing's contributions, and updated longer term revenue guidance.Seeking Alpha • Aug 21
Like The Knick's, Corcept Rebounded And Is Crushing It
Summary Corcept Therapeutics is rated Strong Buy with $163 one-year and $222 two-year price targets, driven by explosive revenue and margin expansion. Lifyorli’s rapid launch for platinum-resistant ovarian cancer and Korlym’s resilient growth underpin 44%+ revenue growth and 98% gross margins, fueling EPS leverage. Based on my Lifyorli model, Street revenue and EPS estimates could be significantly low. Upcoming catalysts include an FDA decision on Relacorilant for Cushing syndrome, European approvals, and key trial results, with significant upside if milestones are met. CORT’s broad pipeline, cash-rich balance sheet, and aggressive salesforce expansion position it as a platform company addressing major disease categories. Read the full article on Seeking Alpha
내러티브 업데이트 • Aug 20
CORT: Ovarian Cancer Launch Will Shape Future Upside Outlook
Corcept Therapeutics' updated analyst price target has shifted from $88 to $141, reflecting analysts' focus on higher projected revenue growth, a revised future P/E near 21, and the potential impact of products like relacorilant and Lifyorli highlighted in recent research. Analyst Commentary Recent research on Corcept Therapeutics gives you a mix of strong optimism and pointed caution.
내러티브 업데이트 • Aug 06
CORT: Elevated Expectations Around Cushing’s Decision Will Shape Bearish Risk Outlook
Corcept Therapeutics' updated fair value estimate has moved from $88 to $50. This reflects analysts' wider range of views after several firms sharply raised their price targets into the $95 to $165 band, based on stronger recent results, expanded 2026 revenue guidance, and growing confidence in Lifyorli, Korlym, and the broader pipeline.분석 기사 • Aug 05
We Think That There Are More Issues For Corcept Therapeutics (NASDAQ:CORT) Than Just Sluggish Earnings
Following the release of a lackluster earnings report from Corcept Therapeutics Incorporated ( NASDAQ:CORT ) the stock...내러티브 업데이트 • Jul 23
CORT: Regulatory Reset And New Indications Will Shape Balanced Risk Reward Outlook
For Corcept Therapeutics, the analyst-derived fair value estimate has been revised from $50 to $88, with analysts linking the higher target and increased assumed revenue growth to recent positive relacorilant regulatory updates and the potential for an additional indication. Analyst Commentary Recent research around Corcept Therapeutics highlights a mix of optimism around relacorilant and Lifyorli alongside pockets of caution, which matters if you are weighing how much execution or regulatory risk to price into the stock.내러티브 업데이트 • Jul 09
CORT: Regulatory Uncertainty Around Key NDA Resubmission Will Drive Future Downside Risk
Corcept Therapeutics' updated analyst price target of $50, down from $95, reflects analysts incorporating lower projected revenue growth, a slightly higher discount rate, and a more conservative future P/E multiple, even as they factor in improved profit margin assumptions and recent positive relacorilant and Lifyorli milestones. Analyst Commentary Recent Street research on Corcept Therapeutics has centered on the regulatory path for relacorilant, the commercial outlook for Lifyorli in ovarian cancer, and how these factors feed into valuation assumptions.내러티브 업데이트 • Jun 25
CORT: Ovarian Cancer Launch And Cushing’s Review Will Shape Balanced Outlook
Analysts have lifted their price targets on Corcept Therapeutics to a range of $72 to $135, citing the positive relacorilant NDA resubmission, the recent Lifyorli approval, and greater clarity on the regulatory path as key reasons for the higher valuation views. Analyst Commentary Recent research on Corcept Therapeutics points to a more constructive view on the stock, with several firms lifting price targets after the relacorilant NDA resubmission and the approval of Lifyorli.내러티브 업데이트 • Jun 06
CORT: Ovarian Cancer Data And Cushing’s Resubmission Will Drive Future Upside
Corcept Therapeutics' updated analyst price target has increased to $88.00 from $73.40, reflecting analysts' focus on recent price target revisions associated with the relacorilant NDA resubmission and the launch of Lifyorli in ovarian cancer. Analyst Commentary Recent Street research around Corcept Therapeutics centers on two main themes, the relacorilant regulatory path and the commercial opportunity for Lifyorli in ovarian cancer, with both feeding directly into updated valuation work.내러티브 업데이트 • May 11
CORT: New Ovarian Cancer Therapy Approval Will Support Future Upside
Analysts have raised Corcept Therapeutics' implied fair value target to $73.40 from $67.40. This reflects updated assumptions that indicate higher revenue growth and profit margins, slightly offset by a higher discount rate and a lower future P/E multiple following recent mixed price target revisions and a rating upgrade on the stock.내러티브 업데이트 • Apr 25
CORT: Ovarian Cancer Approval Will Support Future Upside Despite Patent Setback
Analysts have adjusted their price targets on Corcept Therapeutics, with changes such as H.C. Wainwright moving its target to $67, alongside offsetting increases from firms like Canaccord. These moves reflect updated views on patent risk, generic competition and the long term earnings profile implied by largely unchanged fair value, revenue growth, profit margin and future P/E assumptions.내러티브 업데이트 • Apr 11
CORT: Ovarian Cancer Approval Will Support Future Upside Despite Generic Headwinds
Corcept Therapeutics' updated analyst price target has been reset to $67, with analysts citing a tempered revenue growth outlook, slightly stronger expected profit margins, and an unchanged fair value and future P/E assumption. Analyst Commentary Recent Street research on Corcept Therapeutics reflects a mixed but engaged view, with several firms recalibrating price targets and ratings after legal and regulatory updates.내러티브 업데이트 • Mar 27
CORT: Ovarian Cancer Approval Will Drive Future Upside Despite Generic Risk
Corcept Therapeutics' updated analyst price target has moved to $67.40 from $65.40. Analysts cite refined fair value assumptions and a slightly higher future P/E multiple as they reassess the stock following mixed target changes across recent research coverage.내러티브 업데이트 • Mar 10
CORT: Future Generic Ruling And Oncology Data Will Drive Upside
Analysts have reduced their price target on Corcept Therapeutics to $67 from $105, reflecting lower fair value assumptions and revised expectations for revenue growth and profit margins after the court ruling that allows Teva's generic Korlym to participate in the Cushing's syndrome market. Analyst Commentary Recent research on Corcept Therapeutics clusters around the patent ruling on Teva's generic Korlym and its implications for the Cushing's syndrome market.내러티브 업데이트 • Feb 24
CORT: Future Court Ruling And Oncology Data Will Drive Long Term Upside
Analysts have reduced their fair value estimate for Corcept Therapeutics from $94.20 to $76.40 and the implied future P/E from 18.66x to 16.90x, reflecting a lower price target from $105 to $67 following the court decision allowing Teva's generic Korlym to compete, along with a more cautious view on revenue growth and profit margins. Analyst Commentary Recent research updates on Corcept Therapeutics focus heavily on the legal outcome around Teva's generic Korlym and what that could mean for valuation, growth expectations, and execution risk.내러티브 업데이트 • Feb 09
CORT: Future Regulatory And Oncology Outcomes Will Drive Long Term Upside
Analysts have raised their price target on Corcept Therapeutics by about $1, citing updated models that reflect steady assumptions for fair value, revenue growth, profit margins and future P/E. Recent research maintains the overall investment thesis despite regulatory developments.내러티브 업데이트 • Jan 26
CORT: Future Endocrine And Oncology Decisions Will Drive Long Term Upside
Narrative Update: Corcept Therapeutics Analysts have lifted their fair value estimate for Corcept Therapeutics to $94.20 from $91.00, citing updated assumptions around higher revenue growth, stronger profit margins, and a slightly lower future P/E multiple in their latest models. Analyst Commentary Recent research on Corcept Therapeutics has focused on how its Cushing's syndrome franchise could support long term growth, while also highlighting uncertainties around future positioning and execution.내러티브 업데이트 • Jan 10
CORT: Upcoming Endocrine And Oncology Decisions Will Shape Long Term Upside
Analysts have reset their price target framework for Corcept Therapeutics from about $127 to roughly $91, reflecting updated assumptions around revenue growth, profit margins, and a higher future P/E multiple, informed in part by recent coverage that compares relacorilant and Korlym with existing Cushing's syndrome treatments. Analyst Commentary Street research around Corcept Therapeutics is limited in the recent set of notes, but one new initiation helps frame how some investors might think about both the clinical and valuation setup for the stock.분석 기사 • Jan 01
The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56%
Corcept Therapeutics Incorporated ( NASDAQ:CORT ) shareholders that were waiting for something to happen have been...내러티브 업데이트 • Dec 17
CORT: Upcoming Ovarian Cancer Decisions May Drive Upside Despite Pharmacy Transition Risks
Analysts have modestly trimmed their price target on Corcept Therapeutics to $127.20 from $134.50, reflecting a slightly higher discount rate. They also point to stronger long term revenue growth, expanding profit margins and a lower future P E multiple supported by continued confidence in the commercial potential of Korlym and relacorilant.분석 기사 • Oct 07
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable
The Corcept Therapeutics Incorporated ( NASDAQ:CORT ) share price has done very well over the last month, posting an...매출 및 비용 세부 내역
매출 및 비용 세부 내역
Corcept Therapeutics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 30 Jun 26 | 831 | 54 | 556 | 254 |
| 31 Mar 26 | 769 | 47 | 503 | 260 |
| 31 Dec 25 | 761 | 98 | 449 | 255 |
| 30 Sep 25 | 741 | 105 | 402 | 260 |
| 30 Jun 25 | 716 | 132 | 352 | 251 |
| 31 Mar 25 | 685 | 133 | 315 | 249 |
| 31 Dec 24 | 675 | 140 | 280 | 247 |
| 30 Sep 24 | 629 | 140 | 244 | 231 |
| 30 Jun 24 | 570 | 125 | 216 | 217 |
| 31 Mar 24 | 524 | 117 | 192 | 202 |
| 31 Dec 23 | 482 | 105 | 184 | 184 |
| 30 Sep 23 | 450 | 91 | 179 | 166 |
| 30 Jun 23 | 428 | 94 | 169 | 154 |
| 31 Mar 23 | 414 | 94 | 164 | 144 |
| 31 Dec 22 | 402 | 101 | 153 | 131 |
| 30 Sep 22 | 398 | 117 | 143 | 123 |
| 30 Jun 22 | 392 | 113 | 138 | 118 |
| 31 Mar 22 | 380 | 112 | 130 | 113 |
| 31 Dec 21 | 366 | 113 | 122 | 114 |
| 30 Sep 21 | 353 | 106 | 116 | 114 |
| 30 Jun 21 | 343 | 98 | 112 | 119 |
| 31 Mar 21 | 340 | 99 | 107 | 118 |
| 31 Dec 20 | 354 | 106 | 105 | 115 |
| 30 Sep 20 | 356 | 109 | 107 | 111 |
| 30 Jun 20 | 351 | 114 | 104 | 100 |
| 31 Mar 20 | 335 | 106 | 104 | 95 |
| 31 Dec 19 | 306 | 94 | 100 | 89 |
| 30 Sep 19 | 285 | 87 | 95 | 83 |
| 30 Jun 19 | 268 | 78 | 92 | 80 |
| 31 Mar 19 | 258 | 76 | 87 | 78 |
| 31 Dec 18 | 251 | 75 | 81 | 75 |
| 30 Sep 18 | 238 | 152 | 77 | 70 |
| 30 Jun 18 | 216 | 148 | 72 | 63 |
| 31 Mar 18 | 189 | 142 | 66 | 50 |
| 31 Dec 17 | 159 | 129 | 62 | 40 |
| 30 Sep 17 | 130 | 35 | 57 | 33 |
| 30 Jun 17 | 109 | 24 | 52 | 29 |
| 31 Mar 17 | 93 | 13 | 50 | 26 |
| 31 Dec 16 | 81 | 8 | 45 | 24 |
| 30 Sep 16 | 72 | 5 | 42 | 21 |
| 30 Jun 16 | 64 | 1 | 41 | 18 |
| 31 Mar 16 | 56 | -2 | 38 | 16 |
| 31 Dec 15 | 50 | -6 | 37 | 15 |
| 30 Sep 15 | 44 | -11 | 36 | 15 |
양질의 수익: CORT는 고품질 수익을 보유하고 있습니다.
이익 마진 증가: CORT의 현재 순 이익률 (6.5%)은 지난해 (18.4%)보다 낮습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: CORT의 수익은 지난 5년 동안 연평균 2.7% 감소했습니다.
성장 가속화: CORT은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.
수익 대 산업: CORT은 지난 1년 동안 수익이 감소(-58.9%)하여 Pharmaceuticals 업계 평균(1%)과 비교하기 어렵습니다.
자기자본이익률
높은 ROE: CORT의 자본 수익률(7.8%)은 낮음으로 평가됩니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/14 05:13 |
| 종가 | 2026/09/14 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Corcept Therapeutics Incorporated는 19명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Debjit Chattopadhyay | Brean Capital Historical (Janney Montgomery) |
| David Buck | B. Riley Securities, Inc. |